Cases | Controls | Unadjusted | Adjustedab | |||||
---|---|---|---|---|---|---|---|---|
n = 2238 | % | n = 8645 | % | OR | 95% CI | OR | 95% CI | |
Elimination half-life of BZD | ||||||||
Only long-acting BZD | 160 | 7.2 | 502 | 5.8 | 1.35 | 1.12–1.62 | 1.41 | 1.16–1.71 |
Only short-acting BZD | 213 | 9.5 | 692 | 8.0 | 1.29 | 1.10–1.52 | 1.42 | 1.20–1.69 |
Long- + short- acting BZD | 299 | 13.4 | 950 | 11.0 | 1.33 | 1.15–1.53 | 1.61 | 1.37–1.89 |
Non-users | 1566 | 70.0 | 6501 | 75.2 | 1 | 1 | ||
Polypharmacy of BZD and Z-drugs | ||||||||
Only one kind of BZD | 238 | 10.6 | 781 | 9.0 | 1.30 | 1.11–1.52 | 1.40 | 1.19–1.65 |
Two or more kinds of BZD | 309 | 13.8 | 979 | 11.3 | 1.35 | 1.17–1.55 | 1.61 | 1.38–1.89 |
Only Z-drugs | 99 | 4.4 | 337 | 3.9 | 1.26 | 1.00–1.59 | 1.33 | 1.04–1.69 |
One kind of BZD + Z-drugs | 34 | 1.5 | 89 | 1.0 | 1.61 | 1.08–2.40 | 1.65 | 1.08–2.50 |
Two or more kinds of BZD + Z-drugs | 91 | 4.1 | 295 | 3.4 | 1.33 | 1.04–1.70 | 1.58 | 1.21–2.07 |
Non-users | 1467 | 65.6 | 6164 | 71.3 | 1 | 1 |